Trastuzumab Price in India: — Innovator, Biosimilar and Cost Per Cycle

The cost depends on your body weight and which product your hospital uses. Trastuzumab is dosed by weight and given every three weeks on the standard schedule. For many patients, one 440 mg vial covers a single maintenance cycle, but a higher body weight may require a second vial, which roughly doubles the per-cycle cost. Unused drug in a vial is generally discarded rather than stored. Ask your hospital billing team to calculate your specific cost before treatment starts — the figure will be much more accurate than a general estimate.

Yes, for eligible patients at empanelled hospitals. PM-JAY covers HER2-positive breast cancer treatment and trastuzumab is included in the package list. Whether it covers your full course depends on the scheme's package rate and how your hospital submits the claim. If you hold a PM-JAY or state scheme card, bring it at your first oncology appointment. The hospital's scheme desk can confirm whether your treatment plan qualifies and initiate pre-authorisation before your first cycle.

Possibly — but this is a clinical decision your oncologist must make, not a billing or pharmacy call. Regulatory guidance in India allows switching between approved versions of the same biologic, and international oncology bodies have addressed this in published guidance. Whether a switch is appropriate for you depends on how your treatment is going and what your hospital currently stocks. Raise the question with your oncologist rather than asking the pharmacy to substitute. Cost alone is not a sufficient basis for switching without oncologist review.

Yes — DCGI approval requires that a biosimilar demonstrates it behaves the same way in the body and has a comparable clinical effect. This is a more demanding process than approving a generic tablet; it involves laboratory and clinical comparability data. Real-world data from India and other countries where biosimilars have been used for over a decade adds further reassurance. Your oncologist can explain the specific evidence for the biosimilar being recommended for you.

Some exist, though they change over time and not every patient qualifies. Certain biosimilar manufacturers have offered programmes providing free vials after a set number of paid cycles — ask your hospital team which programmes are currently active. NGOs including the Cancer Patients Aid Association have also supported patients with high-cost cancer medicines. The oncology social worker or nurse coordinator at your treatment centre is the best person to ask — they know which programmes are running and can help you apply.

Not necessarily. Trastuzumab prices can change due to NPPA ceiling revisions, changes in procurement costs, and hospital pricing decisions. If you change hospitals mid-treatment, prices may differ significantly. Confirm the current per-vial price with your hospital before each purchase cycle rather than assuming the figure from the start of treatment still applies. If a significant price increase occurs, ask the billing team whether a lower-cost approved option has become available at your centre.